Eli Lilly Exec Speaking At Morgan Stanley Conference Says Company Now Has More Than 30% Share Of New Starts In Oral Obesity Treatment Market,
https://event.webcasts.com/starthere.jsp?ei=1773602&tp_key=ae15b7650f&tp_special=8
Share
Why It Matters
Eli Lilly says it now leads the oral obesity drug market with over 30% of new patients. This shows the company is winning against rivals in a fast-growing business.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.